Cargando…

Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer

COX-2 expression level and prognostic value are still a matter of debate in breast cancer (BC). We addressed these points in the context of PIK3CA mutational status. Based on an interesting study of aspirin efficacy in colorectal cancer, we hypothesized that celecoxib antitumoral activity may be res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tury, Sandrine, Becette, Véronique, Assayag, Franck, Vacher, Sophie, Benoist, Camille, Kamal, Maud, Marangoni, Elisabetta, Bièche, Ivan, Lerebours, Florence, Callens, Céline
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356723/ https://www.ncbi.nlm.nih.gov/pubmed/27835884 http://dx.doi.org/10.18632/oncotarget.13200

Ejemplares similares

Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers
por: Hatem, Rana, et al.
Publicado: (2016)

Altered Expression of Three EGFR Posttranslational Regulators MDGI, MIG6, and EIG121 in Invasive Breast Carcinomas
por: Meseure, Didier, et al.
Publicado: (2020)

Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer
por: Liang, Xu, et al.
Publicado: (2018)

PIK3R1 underexpression is an independent prognostic marker in breast cancer
por: Cizkova, Magdalena, et al.
Publicado: (2013)

Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609)
por: Liang, Xu, et al.
Publicado: (2018)

PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer
por: Spasojevic, Caroline, et al.
Publicado: (2018)

Kindlin‐1 modulates the EGFR pathway and predicts sensitivity to EGFR inhibitors across cancer types
por: Azorin, Paula, et al.
Publicado: (2022)

NF-kappa B genes have a major role in Inflammatory Breast Cancer
por: Lerebours, Florence, et al.
Publicado: (2008)

An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?
por: Liang, Xu, et al.
Publicado: (2019)

MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers?
por: Cizeron-Clairac, Geraldine, et al.
Publicado: (2015)

Gene Expression Profiling Reveals New Aspects of PIK3CA Mutation in ERalpha-Positive Breast Cancer: Major Implication of the Wnt Signaling Pathway
por: Cizkova, Magdalena, et al.
Publicado: (2010)

Multifocal Fixed Drug Eruption with COX-2 Inhibitor-Celecoxib
por: Chugh, Shikha, et al.
Publicado: (2013)

PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups
por: Cizkova, Magdalena, et al.
Publicado: (2012)

Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition
por: El Botty, Rania, et al.
Publicado: (2018)

Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers
por: Coussy, F., et al.
Publicado: (2020)

De Novo ESR1 Hotspot Mutation in a Patient With Endometrial Cancer Treated With an Aromatase Inhibitor
por: Morel, Adeline, et al.
Publicado: (2019)

Update on inflammatory breast cancer
por: Lerebours, Florence, et al.
Publicado: (2005)

Early metabolic response of breast cancer to neoadjuvant endocrine therapy: comparison to morphological and pathological response
por: Boughdad, Sarah, et al.
Publicado: (2020)

Hemoglobin overexpression and splice signature as new features of inflammatory breast cancer?
por: Lerebours, F., et al.
Publicado: (2020)

Selective COX-2 inhibitors, NSAIDs and cardiovascular events – is celecoxib the safest choice?
por: Howes, Laurence Guy
Publicado: (2007)

Gain of Aggressive Histological and Molecular Patterns after Acquired Resistance to Novel Anti-EGFR Therapies in Non-Small Cell Lung Cancer
por: Basse, Clémence, et al.
Publicado: (2023)

Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac
por: Walker, Chris
Publicado: (2018)

Erratum to “Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac”
por: Walker, Chris
Publicado: (2019)

COX2 inhibition in the treatment of COVID-19: Review of literature to propose repositioning of celecoxib for randomized controlled studies
por: Baghaki, Semih, et al.
Publicado: (2020)

Carcinogenesis of PIK3CA
por: German, Sidra, et al.
Publicado: (2013)

ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels
por: Rondeau, S, et al.
Publicado: (2015)

Acquired Exon 14 MET Mutation Associated With Resistance to Alectinib in a Patient With ALK–Rearranged NSCLC
por: Daniel, Catherine, et al.
Publicado: (2020)

Cytokinesis-block micronucleus assay of celecoxib and celecoxib derivatives
por: Reimann, Hauke, et al.
Publicado: (2020)

COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro
por: Chuang, Huan-Ching, et al.
Publicado: (2008)

The selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: An intravital microscopy study in mice
por: Klenke, Frank Michael, et al.
Publicado: (2006)

Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms
por: Liu, B, et al.
Publicado: (2011)

Celecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanisms
por: Liu, B, et al.
Publicado: (2011)

Celecoxib Treatment Alters p53 and MDM2 Expression via COX-2 Crosstalk in A549 Cells
por: Gharghabi, Mehdi, et al.
Publicado: (2016)

Celecoxib, a selective COX-2 inhibitor, markedly reduced the severity of tamoxifen-induced adenomyosis in a murine model
por: Jin, Zhixing, et al.
Publicado: (2020)

PIK3CA in Colorectal Cancer
por: Cathomas, Gieri
Publicado: (2014)

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab
por: Cizkova, M, et al.
Publicado: (2013)

Revisited analysis of a SHIVA01 trial cohort using functional mutational analyses successfully predicted treatment outcome
por: Kamal, Maud, et al.
Publicado: (2018)

Celecoxib exerts protective effects in the vascular endothelium via COX-2-independent activation of AMPK-CREB-Nrf2 signalling
por: Al-Rashed, Fahad, et al.
Publicado: (2018)

Comparative population pharmacokinetics and absolute oral bioavailability of COX-2 selective inhibitors celecoxib, mavacoxib and meloxicam in cockatiels (Nymphicus hollandicus)
por: Dhondt, Laura, et al.
Publicado: (2017)

Distinct expression profiles and functions of Kindlins in breast cancer
por: Azorin, Paula, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5f9r0gg730j3509u146hc57qvt